WHO vaccine-preventable diseases: monitoring system. 2019 global summary

Last updated 15-July-2019 (data as of 1-July-2019)
Next overall update Winter 2019
EPI mother and child logo         
Select a country

Development status: Economy in transition GNI / capita (US$): 10'2301 Infant (under 12 months) mortality rate: 72
GDP / capita (US$): 27'1471 Child (under 5 years) mortality rate: 82

Population data in thousands3

  2018  2017  2016  2015  2014  2000  1990  1980 
Total population 145'734  145'530  145'275  144'985  144'665  146'405  147'532  138'053 
Births 1'842  1'870  1'890  1'899  1'895  1'327  1'999  2'259 
Surviving infants 1'831  1'859  1'877  1'885  1'881  1'302  1'953  2'197 
Pop. less than 5 years 9'497  9'539  9'484  9'315  9'123  6'435  11'521  10'541 
Pop. less than 15 years 26'107  25'663  25'119  24'469  23'812  26'711  33'781  29'769 
Female 15-49 years 68'221  68'542  69'009  69'704  70'477  78'392  71'698  72'745 

Number of reported cases

(Click for retrospective incidence data for Russian Federation (the))
Diphtheria
ChartChart
  771  1'211 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  2'539  721  178  843  4'711  4'800  18'370 
Mumps
ChartChart
  2'027  4'443  1'106  190  267  40'976 
Pertussis
ChartChart
  10'423  5'411  8'232  6'452  4'705  29'983  24'960 
Polio*
 
Rubella
ChartChart
  38  25  72  457'378 
Rubella (CRS)
ChartChart
  11 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  11  13  18  13  33 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Russian Federation (the))
Vaccine year result method % card seen                                                
BCG          95  95  96  96  96  96 
DTP1          97 
DTP3          97  97  97  97  97  96 
IPV1         
HepB_BD         
HepB3          97  97  97  97  97  10 
Hib3         
JapEnc         
MCV1          98  98  98  98  98  97 
MCV2          97  97  97  97  97  86 
MenA         
PCV1         
PCV2          92  88  75 
PCV3          82  70  35 
Pol3          96  96  97  97  97  97 
Rota1         
RotaC         
RCV1          98  98  98  98  98 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2020

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Russian Federation (the))
BCG
ChartChart
  95  95  96  96  96  96 
DTP1
ChartChart
  97  97  97  97  97  97 
DTP3
ChartChart
  97  97  97  97  97  96 
HepB3
ChartChart
  97  97  97  97  97 
HepB_BD
ChartChart
 
Hib3
ChartChart
 
IPV1
  97  97  97  97 
MCV1
ChartChart
  98  98  98  98  98  97 
MCV2
ChartChart
  97  97  97  97  97  86 
PCV3
ChartChart
  82  70  35 
Pol3
ChartChart
  96  96  97  97  97  97 
RCV1
ChartChart
  98  98  98  98  98  97 
RotaC
 

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country 2'350  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 4
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
96
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2018 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 3 days; 7 years; Yes
Dip >10 years; Yes rarely used
DT 4.5 months; 1 year; Yes
DTaPHibHepBIPV 3, 4.5, 6, 18 months; No risk groups
DTaPHibIPV 3, 4.5, 6, 18 months; Yes risk groups
DTwP 3, 4.5, 6, 18 months; Yes
DTwPHepB 6 months; Yes
HepA_Adult 1st contact; +6-12 months; No
HepA_Pediatric >=1 year; +6-12 months; No
HepB_Adult 1st contact; +1, +6 months; Yes
HepB_Pediatric <24 hours; 1, 6 months; Yes
HIB 3, 4.5, 6, 18 months; Yes risk groups
HPV 12-14 years; +1, +6 months; No females
Influenza_Adult >7 years; Yes and elderly, adults with chronic conditions, pregnant women, healthcare workers, residents living in long-term care facilities, Hajj or other travellers, other risk groups
Influenza_Pediatric 6 months-7 years; Yes and children with chronic conditions
IPV 3, 4.5 months; Yes
Measles 12 months; 6, 18-55 years; Yes
MenACWY-135 conj No for epidemics and pilgrims
MM 12 months; 6 years; Yes
MMR 12 months; 6 years; Yes
Mumps 12 months; 6 years; Yes
OPV 6, 18, 20 months; 14 years; Yes
Pneumo_conj 2, 4.5, 15 months; Yes
Pneumo_ps >18 years; No
Rotavirus 2, 4.5 months; No
Rubella 12 months; 6 years; Yes
Td 6-7, 14 years; +10 years; Yes
TT >5 years; Yes
Typhoid_conj >18 years; No
Typhoid_ps 3, 18 years; No
Varicella 12 months; No
YF No travellers to endemic countries

Immunizaton indicators

Indicator Expected answer 2018  2017  2016  2015  2014  2013  2012 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2018-2020  2'020  2'020  2'020       
Nº of districts with microplans that include activities to raise immunization coverage number 85  85  85  85       

System performance

Total Nº districts in country number 2'350        84  83  83 
Nº districts with DTP3 coverage >=80% number 85  85  85  85  83  83  83 
% of districts with DTP3 coverage >=80% From 0 to 100%       99  100  100 
Nº districts with measles (MCV1) coverage >=95% number 84  83  83  84  83  83  83 
% of districts with MCV1 coverage >=95% From 0 to 100%       99  100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  No  No  No  No  No   

Sources

 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.